Inhalable treatment for advanced lung cancer using engineered Influenza A virus
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
['FUNDING_SBIR_2'] · ACCURIUS THERAPEUTICS, INC. · NIH-11166802
This study is testing a new inhalable treatment for lung cancer that has spread, using a specially designed virus to help your body fight the cancer while keeping healthy cells safe, and it’s aimed at improving survival for patients like you.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ACCURIUS THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11166802 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel inhalable treatment for metastatic non-small cell lung cancer (mNSCLC) and other cancers that have spread to the lungs. The treatment utilizes an engineered oncolytic virus derived from the Influenza A virus, designed to selectively target and destroy cancer cells while preserving healthy cells. The approach aims to enhance the body's immune response against tumors, potentially leading to improved survival rates for patients. The research will involve preclinical studies to identify the most effective virus candidates and assess their efficacy in combination with existing immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer or other cancers that have metastasized to the lungs.
Not a fit: Patients with early-stage lung cancer or those whose cancer has not spread to the lungs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking inhalable therapy that significantly improves survival rates for patients with advanced lung cancer.
How similar studies have performed: While the use of oncolytic viruses in cancer treatment is an emerging field, this specific approach using engineered Influenza A virus is novel and has not been extensively tested in clinical settings.
Where this research is happening
LEXINGTON, UNITED STATES
- ACCURIUS THERAPEUTICS, INC. — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SRIVATSAN, MALLIKARJUN — ACCURIUS THERAPEUTICS, INC.
- Study coordinator: SRIVATSAN, MALLIKARJUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, Cancer Patient, CancerModel